- Conditions
- Healthy Participants, Alzheimer's Disease Dementia
- Interventions
- Emraclidine, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- Cypress, California • San Diego, California • Hialeah, Florida + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Schizophrenia
- Interventions
- Emraclidine 15 mg, Emraclidine 30 mg, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 19
- States / cities
- Bentonville, Arkansas • Bellflower, California • La Habra, California + 15 more
- Conditions
- Healthy Participants
- Interventions
- Emraclidine
- Drug
- Lead sponsor
- Cerevel Therapeutics, LLC
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Schizophrenia
- Interventions
- 10 mg CVL-231 as IR formulation, 30 mg CVL-231 as slow-release MR formulation, 30 mg CVL-231 as medium release MR formulation, 30 mg CVL-231 as fast release MR formulation, 30 mg CVL-231 Target Release, Fasted, 30 mg CVL-231 Target Release, Fed
- Drug
- Lead sponsor
- Cerevel Therapeutics, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Schizophrenia
- Interventions
- Placebo, Emraclidine 10 mg, Emraclidine 30 mg
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • Anaheim, California • Garden Grove, California + 18 more
- Conditions
- Healthy Participants
- Interventions
- Treatment A: Emraclidine 30mg IR tablets (reference), Treatment B: Emraclidine 30mg IR test tablets 1, Treatment C: Emraclidine 30mg IR test tablets 2, Treatment D: Emraclidine 30mg IR test tablets 3
- Drug
- Lead sponsor
- Cerevel Therapeutics, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Hepatic Impairment
- Interventions
- Emraclidine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • San Antonio, Texas
- Conditions
- Schizophrenia
- Interventions
- CVL-231
- Drug
- Lead sponsor
- Cerevel Therapeutics, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Renal Impairment
- Interventions
- Emraclidine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 5
- States / cities
- Tustin, California • Miami, Florida • Orlando, Florida + 1 more
- Conditions
- Healthy Participants
- Interventions
- Emraclidine, Esomeprazole
- Drug
- Lead sponsor
- Cerevel Therapeutics, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Dilworth, Minnesota
- Conditions
- Schizophrenia
- Interventions
- Emraclidine 30 mg
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 62
- States / cities
- Phoenix, Arizona • Bryant, Arkansas • Little Rock, Arkansas + 46 more
- Conditions
- Schizophrenia
- Interventions
- CVL-231, Matching Placebo
- Drug
- Lead sponsor
- Cerevel Therapeutics, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Lemon Grove, California + 2 more
- Conditions
- Blood Pressure, Schizophrenia
- Interventions
- CVL-231
- Drug
- Lead sponsor
- Cerevel Therapeutics, LLC
- Industry
- Eligibility
- 30 Years to 60 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 10
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Long Beach, California + 7 more